Literature DB >> 12914966

Reduction of energy metabolism in rat hippocampus by arginine administration.

Débora Delwing1, Bárbara Tagliari, Emílio Luiz Streck, Clovis Milton Duval Wannamacher, Moacir Wajner, Angela Terezinha de Souza Wyse.   

Abstract

Hyperargininemia is an inherited metabolic disease biochemically characterized by tissue accumulation of arginine. Mental retardation and other neurological features are common symptoms in hyperargininemic patients. Considering that the underlying mechanisms of brain damage in this disease are poorly established, in this work we investigated the effect of arginine administration to adult Wistar rats on some parameters of energy metabolism (CO(2) production, glucose uptake, lactate release and the activities of succinate dehydrogenase, complexes II and IV of the respiratory chain) in rat hippocampus. The action of L-NAME, an inhibitor of oxide nitric oxide synthase, on the effects produced by arginine was also tested. Sixty-day-old rats were treated with a single intraperitoneal injection of saline (group I, control), arginine (0.8 g/kg) (group II) or arginine (0.8 g/kg) plus L-NAME (2 mg/kg) (group III) and were killed 1 h later. Results showed that arginine administration significantly increased lactate release and diminished CO(2) production, glucose uptake, succinate dehydrogenase and complex II activities. In contrast, complex IV (cytochrome c oxidase) activity was not changed by this amino acid. Furthermore, simultaneous injection of L-NAME prevented some of these effects, except CO(2) production and lactate release. The present data indicate that in vivo arginine administration impairs some parameters of energy metabolism in hippocampus of rats probably through NO formation.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12914966     DOI: 10.1016/s0006-8993(03)03029-4

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  8 in total

1.  Creatine prevents the inhibition of energy metabolism and lipid peroxidation in rats subjected to GAA administration.

Authors:  Janaína Kolling; Angela T S Wyse
Journal:  Metab Brain Dis       Date:  2010-09-10       Impact factor: 3.584

2.  Arginine administration reduces creatine kinase activity in rat cerebellum.

Authors:  Débora Delwing; Andrea R Cornélio; Moacir Wajner; Clóvis M D Wannmacher; Angela T S Wyse
Journal:  Metab Brain Dis       Date:  2007-01-18       Impact factor: 3.584

3.  Alpha-tocopherol and ascorbic acid administration prevents the impairment of brain energy metabolism of hyperargininemic rats.

Authors:  Débora Delwing; Bárbara Tagliari; Fábria Chiarani; Clovis M D Wannmacher; Moacir Wajner; Angela Terezinha de Souza Wyse
Journal:  Cell Mol Neurobiol       Date:  2006-04-18       Impact factor: 5.046

4.  Protective effect of antioxidants on cerebrum oxidative damage caused by arginine on pyruvate kinase activity.

Authors:  Débora Delwing; Daniela Delwing de Lima; Bianca Scolaro; Gabriela G Kuss; José G P Cruz; Angela T S Wyse
Journal:  Metab Brain Dis       Date:  2009-08-26       Impact factor: 3.584

5.  Inhibition of CO(2) production from glucose by arginine in brain slices of rats.

Authors:  Débora Delwing; Francieli M Stefanello; Marcos L S Perry; Angela T S Wyse
Journal:  Metab Brain Dis       Date:  2007-05-22       Impact factor: 3.584

6.  NTPDase and 5'-nucleotidase activities of synaptosomes from hippocampus of rats subjected to hyperargininemia.

Authors:  Débora Delwing; Daniela Delwing; Manuela C F Gonçalves; João J F Sarkis; Angela T S Wyse
Journal:  Neurochem Res       Date:  2007-03-31       Impact factor: 4.414

7.  Argininemia as a cause of severe chronic stunting and partial growth hormone deficiency (PGHD): A case report.

Authors:  Xiaotang Cai; Dan Yu; Yongmei Xie; Hui Zhou
Journal:  Medicine (Baltimore)       Date:  2018-02       Impact factor: 1.817

8.  Serum Metabolomic Analysis of Chronic Drug-Induced Liver Injury With or Without Cirrhosis.

Authors:  Shuai-Shuai Chen; Ying Huang; Yu-Ming Guo; Shan-Shan Li; Zhuo Shi; Ming Niu; Zheng-Sheng Zou; Xiao-He Xiao; Jia-Bo Wang
Journal:  Front Med (Lausanne)       Date:  2021-03-29
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.